This study examined what types of subjects may benefit from the use of multiple memory hearing aids that offer variation in their frequency response characteristics. Thirty subjects with varied degrees and configurations of hearing loss compared an individually prescribed frequency response (NAL) and two variations in which the real-ear response slope was either increased (more high-frequency emphasis) or decreased by about 3 dB/octave over the range from 500 Hz to 4000 Hz. The evaluations consisted of paired comparison judgments of pleasantness and of ease of understanding speech, in quiet and in three background noises with substantially different acoustic spectra (traffic noise, speech babble, and high-frequency noise). Twelve of the 30 subjects selected different frequency responses for different background noises and/or for different response criteria. These subjects were characterized as having the more severe high-frequency hearing losses (averaged across 2000, 3000, and 4000 Hz). They also tended to be those for whom the three frequency responses provided the greatest variation in real-ear low-frequency gain. (Despite substantial electronic variations, some subjects received only small variations in real-ear gain at the low frequencies). When subjects chose a different response for different conditions, they tended to prefer responses for which the slope was negatively related to the spectrum of the stimulus. This was true for both response criteria. The conclusion is that hearing aid users with substantial high-frequency losses, and who can be fitted with sufficient variation in the low-frequency real-ear gain, have the potential to benefit from having a choice of frequency response characteristics.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/00003446-199512000-00003 | DOI Listing |
J Infect Dev Ctries
December 2024
Students' Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Introduction: Inflammation plays a role in coronavirus disease 2019 (COVID-19) pathophysiology and anti-inflammatory drugs may help reduce the disease severity. Levamisole is an anthelmintic drug with immunomodulatory and possible antiviral effects. This study aimed to evaluate the role of levamisole in the treatment of patients with COVID-19.
View Article and Find Full Text PDFIntroduction: China implemented a dynamic zero-COVID strategy to curb viral transmission in response to the coronavirus disease 2019 (COVID-19) pandemic. This strategy was designed to inhibit mutation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19. This study explores the dynamics of viral evolution under stringent non-pharmaceutical interventions (NPIs) through real-world observations.
View Article and Find Full Text PDFBMC Public Health
January 2025
School of Public Health, Southeast University, Nanjing. 87 Dingjiaqiao Road, Nanjing, China.
Background: Triglyceride-glucose (TyG) index was regarded as a cost-efficient and reliable clinical surrogate marker for insulin resistance (IR), which was significantly correlated with cardiovascular disease (CVD). However, the TyG index and incident CVD in non-diabetic hypertension patients remains uncertain. The aim of study was to explore the impact of TyG index level and variability on risk of CVD among non-diabetic hypertension patients.
View Article and Find Full Text PDFSci Rep
January 2025
Laboratory of Pharmacology, Department of Pharmacy, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.
Recently, exposure to sounds with ultrasound (US) components has been shown to modulate brain activity. However, the effects of US on emotional states remain poorly understood. We previously demonstrated that the olfactory bulbectomized (OBX) rat depression model is suitable for examining the effects of audible sounds on emotionality.
View Article and Find Full Text PDFSci Rep
January 2025
Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey.
Management of melanoma has changed significantly with the discovery of targeted therapies and immune checkpoint inhibitors (ICI). Our aim in the study is to determine which treatment alternatives, specifically dabrafenib plus trametinib and ICIs, are effective in adjuvant therapy and which treatment is effective as first-line metastatic therapy. This retrospective, multicenter study included 120 patients diagnosed with stage IIIB-IIID melanoma receiving both adjuvant and first-line metastatic treatment between 2007 and 2023.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!